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Abstract
Background People in prison experience a range of physical and mental health problems. Evaluating the effectiveness and 
efficiency of prison-based interventions presents a number of methodological challenges. We present a case study of an 
economic evaluation of a prison-based intervention (“Engager”) to address common mental health problems.
Methods Two hundred and eighty people were recruited from prisons in England and randomised to Engager plus usual 
care or usual care. Participants were followed up for 12 months following release from prison. The primary analysis is the 
cost per quality-adjusted life year (QALY) gained of Engager compared to usual care from a National Health Service (NHS) 
perspective with QALYs calculated using the CORE 6 Dimension. A cost-consequences analysis evaluated cross-sectoral 
costs and a range of outcomes.
Results From an NHS perspective, Engager cost an additional £2737 per participant (95% of iterations between £1029 and 
£4718) with a mean QALY difference of − 0.014 (95% of iterations between − 0.045 and 0.017). For the cost-consequences, 
there was evidence of improved access to substance misuse services 12 months post-release (odds ratio 2.244, 95% confi-
dence Interval 1.304–3.861).
Conclusion Engager provides a rare example of a cost-utility analysis conducted in prisons and the community using patient-
completed measures. Although the results from this trial show no evidence that Engager is cost-effective, the results of the 
cost-consequences analysis suggest that follow-up beyond 12 months post-release using routine data may provide additional 
insights into the effectiveness of the intervention and the importance of including a wide range of costs and outcomes in 
prison-based economic evaluations.
Trial registration (ISRCTN11707331).
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Introduction
As of July 2020, there were approximately 80,000 peo-
ple in prison in England and Wales, of which 96% are 
men and 95% are over the age of 18 [1]. People in prison 
experience significant physical and mental health prob-
lems compared to their peers in the community. People in 
prison are around 10 times more likely to have a mental 
health problem than the general population, with over half 
of the men in prison experiencing common mental health 
problems, which include anxiety, depression, phobias, 
obsessive compulsive disorder (OCD) and post-traumatic 
stress disorder (PTSD). Physical health care needs are also 
greater in the prison population and prisoners have higher 
mortality rates than their non-incarcerated peers [2]. The 
aim of prison though is punishment through the removal 
of liberty, maintaining the safety of the community and 
rehabilitation prior to release into the community, aims 
that can sometimes conflict with addressing the mental 
and physical health of people in prison [3]. The cause of 
the health concerns for people in prison may also originate 
from a range of sources including housing, employment, 
finances and relationships which require the involvement 
of multiple agencies to address. Meeting the physical and 
mental health care needs of people in prison population 
presents the health care, social care, welfare, housing and 
criminal justice agencies with challenges, both in terms of 
the logistics of working together to coordinate care as well 
as the significant resources required to meet the needs of 
this population.
Commissioning physical and mental health care in Eng-
lish prisons has been the responsibility of the National 
Health Service (NHS) since 2006 [4]. Mental health care 
in prison is provided by in-reach teams, with a number of 
models of delivery, the aim being to achieve an equivalence 
between mental health care in prisons and in the community. 
As a result there is some evidence that the mental health care 
in prisons is improving [5]. This care though covers special-
ist mental health care focussing on serious mental illness. 
In England, the diagnosis and treatment for common mental 
health problems is the responsibility of General Practitioners 
(GPs) and the Improving Access for Psychological Therapies 
(IAPT) service. However, the latter is not routinely delivered 
in prison settings. There is evidence that those in contact 
with the criminal justice system, whether in prison or the 
community, do not have their common mental health needs 
met: Byng et al. [6] found that 59% of people in contact 
with criminal justice had a common mental health problem, 
although only 61% felt they received the medication and 
32% the therapy they needed. People also experience prob-
lems with continuity of care when they move from prison 
into the community.
In the United Kingdom (UK), there has been concern 
in the past regarding the financial pressure associated with 
providing health care in prisons [3]. In response, there has 
been an increased interest in identifying interventions that 
make best use of limited resources. In the UK, Her Majesty’s 
(HM) Treasury’s Green Book sets out the methodology for 
the evaluation of government-funded programmes. It specifi-
cally recommends the use of cost–benefit analysis (CBA), 
the monetary valuation of all costs and consequences of an 
intervention compared to current practice, for the evalua-
tion of programmes over cost-effectiveness analysis (CEA), 
the cost per outcome gained of one intervention compared 
to another, due to the more restrictive nature of CEA [7]. 
Health care though is a noted exception given the difficulty 
of assigning monetary values to health outcomes. Instead, 
the recommended methodology for economic evaluations of 
health care interventions is a cost-utility analysis (CUA) cal-
culated as the incremental cost per quality-adjusted life year 
(QALY) gained [7–10]. QALYs are calculated by combining 
information about mortality and morbidity into a single unit. 
This is to be done in a standardised way so as to allow for the 
comparison of costs and consequences across programmes 
of work and disease areas in health care, where best practice 
in England is to calculate morbidity from a preference-based 
tariff of health-related quality of life, most commonly using 
the Euroqol EQ-5D [8–10]. A systematic review conducted 
in 2017 of economic evaluations in the diagnosis and man-
agement of mental health problems for adults who are in 
contact with the criminal justice system did not identify 
any economic evaluations of prison interventions for com-
mon mental health problems or for mental health treatment 
more widely. Most economic evaluations instead focussed 
on programmes that divert people with serious mental ill-
ness away from prison or substance misuse treatment. The 
most common economic evaluation type was CEA, with no 
CUAs conducted [11]. Since the review was completed, the 
Critical time Intervention for Severely mentally ill prisoners 
(CrISP) study has been published which reported an array 
of cost information. Although the study collected resource 
use, there was no self-reported measure of health or quality 
of life included, hence a CUA was not conducted [12].
The aim of this paper is to report the results of an eco-
nomic evaluation of the Engager intervention plus usual care 
compared to usual care using participant level trial data over 
12 months following release from prison. Trial participants 
completed a range of patient-reported preference-based 
measures of mental and physical health-related quality of 
life and capability. They also completed a comprehensive 
battery of resource use questionnaires. The primary aim of 
the evaluation is to calculate the mean incremental cost per 
quality-adjusted life year (QALY) gained following release 
from prison and from an NHS perspective. The paper also 
investigates the cost impact of Engager plus usual care 
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compared to usual care on a range of different public sec-
tor budgetary perspectives as well as including productivity 
gains. Costs are included alongside wider consequences to 
inform a cost-consequences analysis.
Methods
Two investigation centres (south–west and north–west of 
England) recruited patients to a parallel, two-group, ran-
domised control trial. Participants were randomised with an 
1:1 allocation to either the Engager Intervention plus usual 
care (the intervention group) or usual care alone (the control 
group). Participants were included in the study if they were 
serving a prison sentence of 2 years or less in a male prison 
in England, with between 4 and 20 weeks remaining of their 
sentence and were identified as having or likely to have com-
mon mental health problems, including anxiety, depression, 
phobias, OCD and PTSD. Men were excluded if they met 
any of the following criteria: they were unable to provide 
consent; were on remand; had a serious and enduring men-
tal health disorder including being on the caseload of the 
prison in-reach team; had a primary personality disorder; 
presented a serious risk of harm to the trial and intervention 
delivery team; or posed a risk of harm to themselves and 
the healthcare team felt participation in the study would be 
detrimental.
The primary objective of the trial was to evaluate the 
effectiveness of the Engager intervention in improving 
psychological and social outcomes for men with common 
mental health problems in prison, with a primary outcome 
of the Clinical Outcomes in Routine Evaluation Outcome 
Measure (CORE-OM) measured at 6 months after release 
from prison. The study was approved by the UK National 
Health Service, Wales Research Ethics Committee 3 (ref: 
15/WA/0314) and the National Research Committee of Her 
Majesty’s Prison and Probation Service (ref 2015–283). Fur-
ther details on the trial are available in the trial protocol [13], 
feasibility [14, 15] and results papers [16]. A number of trial 
processes and outcomes were informed by a feasibility trial 
on Engager run prior to the full trial.
Engager intervention
Participants randomised to the intervention arm received the 
Engager intervention delivered by an Engager practitioner: 
a manualised, person centred intervention with the aim of 
meeting participants mental health needs. These included 
addressing wider support issues such as education, accom-
modation, social relationships and financial management 
that may be related to mental health. Prior to release the 
Engager practitioner worked with participants on goals and 
needs using a goal attainment plan. On release from prison 
ongoing work between the participant practitioner included 
signposting to key community services to address the par-
ticipants needs. All of this was underpinned by practitioners 
offering a mentalisation-based approach to support.
Participants allocated to usual care continued with exist-
ing service provision for men prior to and following release 
from prison which included primary care, secondary care 
(specialist) mental health services, substance misuse ser-
vices and other criminal justice and third-sector organi-
sations that would provide support regarding education, 
accommodation, social relationships and financial manage-
ment as standard.
Cost of engager intervention
The cost of the Engager intervention includes the time of an 
Engager practitioner from a range of different disciplines 
including psychology, mental health nursing, substance mis-
use and housing at the level of assistant practitioner or entry 
level counsellor (NHS pay grade Band 4, £32 per hour [17]) 
to deliver the intervention, plus an allocation of the initial 
cost of training and supervision from a senior practitioner 
from a similar wide range of disciplines at Clinical Psy-
chologist or Specialist level (NHS pay grade Band 7, £56 per 
hour [17]). Training and supervision costs were calculated 
as the time allocated to attend training sessions multiplied 
by the cost of practitioner and supervisor time; the cost of 
delivering the training and mentalisation-based approach 
(MBA) sessions; regular practitioner supervision; and meta-
supervision conducted by a senior clinician (senior clinical 
consultant, £111 per hour [17]). As a conservative estimate 
(overestimate of the true cost if this was implemented as 
part of routine care at a larger scale), the cost per participant 
of training and supervision is calculated as the total cost of 
training and supervision for the whole Engager trial divided 
by the number of participants randomised to the intervention 
arm of the trial. Practitioners were directed to keep detailed 
records of the amount of time they spent delivering differ-
ent aspects of the Engager intervention. This information 
was then transcribed into a database so that the cost of the 
intervention could be calculated for each participant in the 
intervention arm.
A top–down costing of the intervention has been included 
as a sensitivity analysis, costing staff involved in the inter-
vention based on total full time equivalent staff including 
oncosts and overheads [17]. The total cost per participant is 
calculated as the total top–down cost of staff plus the addi-
tional cost of training divided by the number of participants 
in the intervention arm of the trial.
Data on additional services that participants were sign-
posted to and attended as part of the intervention were col-
lected using the resource use questionnaires, as described 
in the next section.
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Resource use and costs
Resource use in both groups was collected using a version 
of the Client Service Receipt Inventory (CSRI) [18] adapted 
based on the experience of the Engager feasibility trial [14]. 
The CSRI was broken into key areas with examples of ser-
vices in each area provided. It also asked if the service use 
was planned or unplanned/emergency. Mental and physical 
health care (planned and emergency) including medication 
was self-reported at baseline, 6 months and 12 months post-
release asking about the previous 3 months at baseline and 
since last follow-up at 6 and 12 months. Accommodation, 
education, training, employment, financial advice, relation-
ship and criminal-related service use was self-reported at 
baseline, pre-release, 6 and 12 months post-release, ask-
ing about the previous 3 months at baseline and since last 
follow-up at pre-release, 6 and 12 months. Participants were 
asked to report number of contacts as well as average dura-
tion of contacts. Unit costs and sources used to calculate 
costs are reported in Table 1. Medication was costed using 
the British National Formulary [19].
Traditionally employment costs are costed as wages or 
salary lost due to illness or interrupted employment. People 
in contact with criminal justice, however, have relatively 
low employment rates: prior to incarceration 33% of the 
Engager trial population were in paid employment. Rather 
than preventing the reduction of productivity through illness, 
the Engager intervention aims to facilitate access to paid 
employment. As a result, employment costs were costed as 
productivity gains using the human capital approach and 
assuming an hourly gross wage of £18.50 [38], which is the 
mean wage for men. Insufficient information was provided 
to use a job specific wage for each trial participant, but this 
value is close to the mean hourly wage for the construction 
industry (£17.29) [39], the most common area that the trial 
participants worked in where information was available. The 
total productivity gain per participant was then subtracted 
from total per participant costs.
All costs are reported in 2017/2018 British Pounds, the 
most recent year costing data were available for. Any costs 
for earlier years were adjusted for the current year using 
the hospital and community health services (HCHS) index 
for health and social care costs [17], and using the Services 
Producer Prices Index [39] for other costs.
Outcome measures
Limited work has been done on determining suitable out-
come measures for economic evaluations of interventions 
delivered in prisons. The choice of outcome measures for 
use in the trial was based on a Delphi exercise evaluating 
which outcome measures to use [40]. As part of the feasibil-
ity trial we identified which outcomes out of the CORE-OM 
[41], Euroqol EQ-5D 5 level (EQ-5D-5L) [42] and ICEpop 
CAPability Adult version (ICECAP-A) [43] were most sen-
sitive to changes in the clinical measure of depression (PHQ-
9) [44] and anxiety (GAD-7) [45], with CORE-OM being 
the most sensitive [15]. The CORE-OM was also chosen as 
the primary outcome of the main effectiveness analysis of 
the trial. The CORE-OM, a 34 item measure covering well 
being, problems/symptoms, life functioning and risk to self 
and others, designed to measure individual differences at the 
start of therapy and how these change over time [41], has 
an associated preference-based tariff, the CORE 6 Dimen-
sion (CORE-6D), that can be used in economic evaluations 
to calculate quality-adjusted life years (QALYs) [46]. As 
a result, our predetermined primary analysis for the eco-
nomic evaluation was to calculate QALYs using the CORE-
6D. The CORE-OM was collected at baseline, 1, 3, 6 and 
12 months post-release from prison, applying the algorithm 
from Mavranezouli et al. [46] to calculate utility for the cost 
per QALY analysis. The EQ-5D-5L and ICECAP-A were 
collected at baseline, 3, 6 and 12 months post-release from 
prison. Utility from the EQ-5D-5L was calculated from 
(a) the van Hout mapping algorithm to the EQ-5D-3L rec-
ommended by that National Institute of Health and Care 
Excellence (NICE) [47]; (b) the EQ-5D-5L value set [48]. 
ICECAP-A capability was calculated based on the tariff 
developed by Flynn et al. [49].
Statistical analysis
Analyses were pre-specified in a health economics analysis 
plan (HEAP see Supplementary Material 1).
We calculated complete case (participants that were fol-
lowed up at that time point and completed that section of 
the questionnaire) descriptive statistics for the percentage of 
participants and mean number of contacts for each type of 
resource use. As questionnaires were completed with the aid 
of a research assistant, we assumed that if a value was miss-
ing for a resource use item it was because the participant did 
not use that item and hence it was imputed as 0. Question-
naires for participants that were followed that were specified 
as missing though were included as missing. Complete case 
means and standard deviations for costs were also calcu-
lated. The mean difference in costs, 95% confidence interval 
and p value for each resource use type was calculated using 
regression analysis adjusting for baseline costs, with centre 
as a covariate and bias-corrected bootstrapping with 3000 
iterations for complete cases (available at all time-points).
QALYs were calculated as the area under the curve 
[10] using the CORE-6D and EQ-5D-5L. People that 
died before they reached a specific follow-up point are 
included as 0 for each follow-up point after they died, 
assuming a straight line from their last complete ques-
tionnaire until death. Years of Full Capability (YFC) 
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Table 1  Resource use unit costs in 2017/2018 British Pounds
Resource use Unit cost References
Health care resource use
 Hospital transfer (community) 258 NHS Reference Costs [20]
 Hospital transfer (prison) 4548 Department of Health [21]
 Alcohol brief intervention (delivered by nurse) 8 PSSRU [17]
 Community mental health nurse (per h) 34 PSSRU [17]
 Counselling (per contact) 74 NHS Reference costs [20]
 Criminal justice liaison service (per contact) 234 NHS Reference costs [20]
 Dentist 164 NHS Reference costs [20]
 Cognitive behavioural therapy (per contact) 74 NHS Reference costs [20]
 GP (prison and community; per contact) 28 PSSRU [17]
 Home help/care worker (per h) 28 PSSRU [17]
 Substance misuse services: prison (per contact) 80 PSSRU prison [22]
 Substance misuse services: community (per contact) 130 NHS Reference costs [20]
 Mental health clinic (per contact) 160 NHS Reference costs [20]
 NHS walk-in centres 35 Estimated using PSSRU [17]
 Occupational therapist (per contact) 81 NHS Reference costs [20]
 Optician (per contact) 54 Violato [23]
 Peer groups for substance misuse (with Band 5 counsellor leading—per contact) 34 PSSRU [17]
 Physiotherapist (per contact) 57 NHS Reference costs [20]
 Practice nurse (per h) 37 PSSRU [17]
 Prison nurse (per h) 37 PSSRU [17]
 Psychiatrist (per h) 111 PSSRU [17]
 Psychologist (per contact) 74 NHS Reference costs [20]
 Sexual health worker (per contact) 120 NHS Reference costs [20]
Social worker (per h) 45 PSSRU [17]
 Learning difficulties nurse (per contact) 79 NHS Reference costs [20]
 Blood-borne viruses nurse 89 NHS Reference costs [20]
 Behaviour change (per contact) 74 NHS Reference costs [20]
 Pharmacy—dispensing cost (per contact) 9 PSNC [24]
 Podiatrist/chiropodist (per contact) 51 NHS Reference costs [20]
 Healthy living (per client) 120 PSSRU [17]
 Smoking cessation (per contact) 15 NICE [25]
 IAPT (per contact) 96 PSSRU [17]
Criminal justice
 Probation worker/community rehabilitation company (CRC) worker (per h) 21 Indeed Salaries [26]
 Enhanced thinking skills 154 PSSRU Prison [22]
 Healthy Relationships Programme (HRP) high (per contact) 148 PSSRU Prison [22]
 HRP moderate (per contact) 121 PSSRU Prison [22]
 Controlling anger (per contact) 114 PSSRU Prison [22]
 Counselling, Assessment, Referral, Advice and Throughcare (CARAT) prison (per contact) 80 PSSRU Prison [22]
 Education course (per attendance) 120 Ipsos Mori [27]
 Prison (per person per year) 40,843 HM PPS [28]
 Police (per contact) 457 Heslin [29]
 Police (per night in custody) 411 Heslin [29]
 Police (per additional day in custody) 1032 Heslin [29]
Local authority
 Citizens advice (per contact) 21a Citizens Advice [30]
 Employment worker/officer (per contact) 68 PSSRU 2015 [31]
 Housing worker/officer (per contact) 25 Schneider [32]
 Supported accommodation (per person per day) 118 PSSRU [17]
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(equivalent) were calculated using the ICECAP-A and 
methods for decision-making set out by the University 
of Birmingham [50]. For the CORE-6D, EQ-5D-5L 
and ICECAP-A, we report the mean values at each time 
point and mean unadjusted QALYs/YFC from baseline 
to 12 months. Mean difference in QALYs and YFC, 95% 
confidence interval and p value were calculated using 
regression analysis adjusting for baseline utility/tariff 
[10], with centre as a covariate and bias-corrected boot-
strapping with 3000 iterations for complete cases (avail-
able at all time-points).
We assumed that data missing at follow-up was miss-
ing at random. Following examination of a range of out-
come measures, we were unable to identify any predictors 
of missingness. Costs, utility scores and the ICECAP-A 
tariff were imputed for the recommended number of 30 
datasets using chained equations (multiple imputation 
using chained equations (MICE)) and predictive mean 
matching [51].
For the incremental cost-effectiveness ratio (ICER), 
we use seemingly unrelated regression (Stata command 
SUREG) to account for the correlation between costs 
and outcomes to calculate the incremental mean cost per 
QALYs/YFC gained of Engager plus usual care compared 
to usual care. We adjusted for baseline and with centre as 
a covariate. The primary analysis was calculated using the 
multiple imputation dataset and bootstrapped results as 
set out by Leurant et al. [52]. The bootstrapped, imputed 
results were used to calculate the CEAC [53, 54]: the 
probability that Engager is cost-effective compared to 
usual care for a range of thresholds for a QALY/YFC 
gained. A cost-effectiveness plane has also been reported.
As the trial-based analysis covers a 12-month duration, 
no discount rate was applied. Analyses were conducted 
using Stata version 16 [55].
Secondary within‑trial analyses
ICERs, CEACs and CEPs will be reported for the following 
analyses:
(i) Health and social care cost perspective using the EQ-
5D-5L for the calculation of QALYS.
(ii) Health and social care cost perspective using the ICE-
CAP-A for the calculation of YFC.
(iii) All costs minus productivity gains and the CORE-6D 
for the calculation of QALYS
(iv) All costs minus productivity gains and the EQ-5D-5L 
for the calculation of QALYS
(v) All costs minus productivity gains and the ICECAP-A 
for the calculation of YFC.
Sensitivity analyses
(1) The Engager intervention is costed based on informa-
tion on contact times reported by Engager practitioners. 
In sensitivity analysis 1, the Engager intervention is 
costed as the top–down costing that includes the total 
cost of employing practitioners based on their FTE. 
This reflects the actual cost to the NHS of delivering 
Engager, including the learning curve of delivering the 
Engager intervention, as well as tasks that may not have 
been reported by the practitioner, particularly adminis-
trative tasks.
(2) If Engager were to be rolled out more widely, the meta-
supervision delivered by a senior clinician is unlikely 
to be included as part of the training and supervision 
included in the cost of the intervention. As a result, 
we conducted a sensitivity analysis where the cost of 
meta-supervision was not included in the training and 
supervision cost.
a £26.8 million in funding and 1,273,000 contacts
b £6.2 million in funding and £78 million in volunteer equivalent time; 3.6 million calls
c £230 per day to keep a church open
Table 1  (continued)
Resource use Unit cost References
 24 h supported accommodation (per person per day) 267 PSSRU [17]
 Social housing (per person per week) 108 PSSRU [17]
 Probation hostel (same as supported accommodation) 118 PSSRU [17]
Other
 Lawyer (per h) 200 Harcourt Barristers Direct [33]
 Legal advocate (per contact) 34 Devine [34]
 Listeners/visitors/samaritans (per contact) 49b Samaritans [35]
 Support from religious organisations (per h) 29c Thornhill Parish Church [36]
 Life coach (per contact) 50 Bidvine [37[
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(3) In the Engager manual, it was stated that supervision 
was to occur on a weekly basis; in reality, it may occur 
less frequently than this, for example on a fortnightly 
basis. We include a sensitivity analysis with fortnightly 
supervision instead of weekly in the training and super-
vision costs.
(4) Removing pre-release costs from the total costing 
as potentially these occurred before participants had 
received the Engager intervention.
(5) There may be an interaction between being randomised 
to the Engager intervention and the pre-release duration 
in prison and other outcomes. A sensitivity analysis 
will include adjusting for the duration in prison pre-
release, included as a covariate in the regression analy-
sis.
Cost‑consequences analysis
Cost-consequences analysis facilitates the comparison 
between costs and a range of outcomes. This is particularly 
important for interventions such as Engager where differ-
ent costs and consequences are likely to fall on a number 
of different public sector budget holders including health 
care, criminal justice and local government, who in England 
are responsible for substance misuse, social care and some 
accommodation services. Modelling work carried out prior 
to the trial also identified the importance of differentiating 
between planned versus unplanned care as a determinant of 
future costs and outcomes [56].
Our initial aim prior to obtaining trial data was to esti-
mate the incremental cost of health and social care including 
the cost of the Engager intervention in the treatment arm 
compared with the incremental number of trial participants 
who had outcomes such as stable accommodation, were in 
employment or had reduced contact with criminal justice 
agencies. The cost and QALY benefits associated with these 
positive gains would then be extrapolated further into the 
future. Within the pre-specified HEAP, this analysis was 
given very broad methodological details as many aspects 
were reliant on the final results.
The analysis carried out as part of the main trial evalu-
ation showed no evidence for participants randomised to 
the Engager intervention being more likely to be in sta-
ble accommodation [17]. There was also no evidence for 
reduced contact with criminal justice agencies, with the 
results suggesting instead the opposite. Instead, we chose 
to investigate if Engager compared to usual care resulted in 
any of the following:
• Greater odds of being in paid employment: calculated 
as an odds ratio adjusting for baseline employment and 
centre.
• Greater odds of accessing education: calculated as an 
odds ratio adjusting for baseline education and centre.
• Greater odds of accessing services to help with finance 
and accommodation: calculated as an odds ratio adjust-
ing for baseline finance and accommodation service use, 
respectively.
• Greater odds of being in contact with substance misuse 
services: calculated as an odds ratio adjusting for base-
line substance misuse need and centre.
• Reduced number of unplanned contacts: calculated using 
general linear models and family (Poisson or negative 
binomial) based on the most suitable model as informed 
by the Akaike Information Criterion (AIC) [57].
The weakness of this approach is that there is limited 
evidence on which to base any potential extrapolation of 
the benefits associated with each of these outcomes. The 
strongest evidence comes from improved access to substance 
misuse services. Although this may seem counterintuitive as 
it implies that the person has a substance misuse issue, for a 
population with a high level of substance misuse need this 
is an extremely important outcome: access to substance mis-
use services has been shown to be associated with reduced 
criminal activity and improved access to stable housing in 
the long term [58].
Results
Between January 2016 and October 2017, 280 eligible par-
ticipants were identified and gave consent to be involved 
in the trial: 140 participants were randomised to Engager 
plus usual care and 140 to usual care (see Fig. 1 for Con-
sort), with 1 person excluded post-randomisation in usual 
care (total 139 in usual care). Baseline characteristics of 
trial participants can be found in Table  2, with further 
details reported in the main effectiveness paper [17]. There 
was an imbalance between the two groups at baseline in 
the proportion in stable accommodation pre-release and in 
paid employment pre-release, with usual care participants 
more likely to be in stable accommodation and/or paid 
employment.
Cost of the engager intervention
The total cost of training and supervision for the duration 
of the Engager trial was £59,303 (see Table 3). Of the 140 
participants randomised to Engager, 129 are included in the 
intervention delivery cost analysis after removing withdraw-
als (n = 5), deaths during intervention delivery (n = 2) and 
participants where no case notes were available (n = 4). If 
the total cost of the training and supervision is divided by the 
140 participants randomised to the intervention, the training 
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and supervision costs £424 per participant. We have used 
the number of participants randomised to the intervention to 
calculate the cost per participant of training and supervision 
as this is more likely to reflect the total number of patients 
receiving the intervention if rolled out, if still a conservative 
estimate (over estimate of costs) as in reality this number 
would be higher.
The cost per participant of the Engager intervention is 
detailed in Table 4. Of the 129 participants where data are 
available, on average they received 5.7 (SD 3.9) sessions 
in prison, with 5 participants (4%) having no contacts with 
practitioners. The average time per session delivered in 
prison was 43 min (SD 17) with an average cost of the prison 
component of the intervention of £149 (SD 124) per trial 
participant, including those who did not have any contact 
with a practitioner in prison. Including only participants 
that had at least one session with a practitioner in prison, 
the average cost per participant is £155 (SD 122). Of the 
129 participants that we have data available for, 61 (47%) 
were met ‘at the gate’ (soon after release) by an Engager 
practitioner, and another 10 (8%) had another form of ‘at 
the gate’ contact (phone call or probation), with an average 
contact time of 215 min (SD 128) and an average cost of £61 
(SD 76) per participant, including those who did not have 
any contact with an intervention practitioner ‘at the gate’. 
A total of 108 (84%) of participants received at least one 
Engager session in the community with the average session 
time for the interventions delivered in the community being 
36 min (SD 42) per session (face-to-face and telephone con-
tacts). The average cost per participant of the community 
Fig. 1  Engager consort diagram
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component of the intervention was £256 (SD 384), includ-
ing those who did not have any contact with a practitioner. 
The total average cost per participant of delivering all inter-
vention sessions (prison, ‘at the gate’ and community) was 
£467 (SD 475). When the cost of training and supervision 
(£424) is added, this is an average cost per participant in the 
Engager arm of £891.
A second way to cost the intervention would be to use 
total staff wages and overheads. The delivery of the inter-
vention required two whole full time equivalent (FTE) NHS 
Band 4 staff and one 0.5 FTE NHS Band 7 staff member 
at each site over the 2 years. Including oncosts and over-
heads as taken from PSSRU [18], the total cost for the two 
Band 4 Engager practitioners per site per year is £95,230 and 
the total cost of the Band 7 0.5 FTE supervisor per year is 
£45,370 for a total cost of £138,800 per site per year. Over 
two sites and two years, this is a total staff and overheads 
cost of £555,200. However, staff turn-over meant that the 
sites were not at their full staff profile for the whole 2 years: 
for 3 months, there was only one Band 4 staff member in 
one site and for a second 3 months, there were no Band 
4 staff members at the other site, hence reducing Band 4 
salaries by a 9-month period £35,711, the total revised cost 
is £519,488. The additional training costs on top of this (see 
Table 2: includes delivery of training and Meta-supervision) 
total £10,215, for a total cost of £529,704. Divided by 140 
participants, this is a total cost per participant of £3784.
Resource use and costs
Descriptive statistics for resource use are reported in Supple-
mentary Material 2. Table 3 reports the mean costs, adjusted 
means and adjusted mean difference adjusting for baseline 
for each cost category and including centre as a covariate. 
The complete case results for costs are reported in Supple-
mentary Material 3.
The mean difference in all health care costs including the 
cost of the Engager intervention and training is £2643 (95% 
CI £590–£4697) per participant, with missing data imputed 
Table 2  Baseline characteristics
Characteristic Engager Usual care
N = 140 N = 139
Age (years); mean (SD) 34 (11.4) 35 (9.9)
Ethnic group; n (%)
 White 128 (93) 133 (96)
 Other 10 (8) 6 (4)
Pre-prison accommodation; n (%)
 Stable 56 (40) 73 (52)
 Unstable 76 (54) 58 (41)
 Enforced 8 (6) 8 (6)
 Other 0 (0) 1 (1)
Educational background; n (%)
 No qualifications 38 (27) 34 (24)
 Basic school level qualifications 41 (29) 41 (29)
 A’ level or equivalent 10 (7) 12 (9)
 Degree/professional qualification 51 (36) 53 (38)
Pre-prison employment status; n (%)
 Full-time/part-time paid employment 28 (20) 40 (29)
 Full-time/part-time self employed 7 (6) 13 (9)
 Other (e.g. voluntary, retired, carer) 1 (1) 2 (1)
 Not working 104 (74) 85 (61)
Pre-prison income source; n (%)
 No source of income 22 (16) 11 (8)
 Employment 30 (21) 40 (29)
 Benefits 77 (55) 78 (56)
 Other 11 (7) 11 (8)
Pre-prison income (£); n (%) N = 138 N = 138
 Less than 13,500 114 (82) 107 (76)
 13,501 or more 24 (17) 31 (23)
Alcohol problem (self-report); n (%) 50/139 (36) 50 (36)
Drug problem (self-report); n (%) 69/139 (50) 60 (43)
CORE-6D; mean (SD) 0.750 (0.168) 0.713 (0.181)
EQ-5D-5L Crosswalk; mean (SD) 0.679 (0.234) 0.657 (0.225)
EQ-5D-5L Tariff; mean (SD) 0.767 (0.186) 0.754 (0.182)
ICECAP-A; mean (SD) 0.613 (0.221) 0.613 (0.226)
Table 3  Total cost of training and supervision
Activity Description Total cost
Training attendance 3 training sessions delivered over 7 days attended by all 4 practitioners and 2 supervisors £8400
MBA session attendance 8 MBA sessions attended by 4 practitioners and 2 supervisors £5760
Training session for new staff 1 training session over 2 days for the 4 new practitioners and 1 new supervisor £1840
Delivery of training Cost of trainer to deliver all 9 sessions £3375
Delivery of MBA session Cost of trainer to deliver 8 MBA sessions £2400
Weekly supervision As directed by the Engager manual, weekly supervision over 2 years and accounting for 1 
practitioner for 3 months in site 1 and no practitioners in site 2 for 3 months
£33,088
Meta-supervision 40 h of face-to-face and phone call contacts over the trial by a senior clinical academic £4440
Total cost of training and supervision £59,303
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Cost of the intervention
 Training and supervision (per person) 424
 Prison component 149 124
 At release 61 76
 Community 256 384
 Total cost per participant (exc training) 467 475
 Total cost per participant (inc training) 891 475
N = 140 N = 139 Adjusted  differencea 95% CI 95% CI p value
Mean SE Mean SE
Specialist mental health
 6 months 116 47 67 30
 12 months 965 592 21 10
 Total (unadjusted) 1081 598 88 32
 Total (adjusted) 1071 503 98 327 973.139 − 209.542 2155.820 0.106
Physical health inpatient-planned
 6 months 17 17 158 147
 12 months 284 116 0
 Total (unadjusted) 302 117 158 147
 Total (adjusted) 301 142 158 122 143.458 − 226.278 513.195 0.445
Physical health inpatient-unplanned
 6 months 300 86 202 89
 12 months 342 137 393 149
 Total (unadjusted) 642 171 596 176
 Total (adjusted) 615 178 622 167 − 6.976 − 494.176 480.224 0.977
Outpatient appointments
 6 months 50 22 38 17
 12 months 38 17 63 31
 Total (unadjusted) 88 27 101 33
 Total (adjusted) 87 30 102 31 − 15.231 − 100.520 70.059 0.724
Community health care
 Pre-release 371 71 316 63
 6 months 1105 161 913 177
 12 months 1483 285 1722 431
 Total (unadjusted) 2959 373 2951 502
 Total (adjusted) 2942 406 2969 466 − 26.637 − 1195.089 1141.815 0.964
Medication
 Total (unadjusted) 196 152 58 18
 Total (adjusted) 193 108 61 109 132.695 − 169.549 434.939 0.388
Total health care
 6 months 1838 232 1515 289
 12 months 3783 750 2257 476
 Total health care (unadjusted) 5019 812 3842 733
 Total (adjusted) 5937 787 4144 687 1793.183 − 257.042 3843.409 0.086
 Total inc. Engager (adjusted) 6789 788 4146 688 2643.315 590.127 4696.502 0.012
Criminal justice service use
 Pre-release 30 23 35 31
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Table 4  (continued)
N = 140 N = 139 Adjusted  differencea 95% CI 95% CI p value
Mean SE Mean SE
 6 months 125 17 160 31
 12 months 135 25 272 118
 Total (unadjusted) 289 40 467 128
 Total (adjusted) 291 73 465 112 − 174.874 − 442.159 92.410 0.196
Prison
 6 months 5179 744 3712 709
 12 months 6141 1182 4021 861
 Total (unadjusted) 11,320 1568 7733 1108
 Total (adjusted) 11,314 1500 7739 1183 3574.627 − 104.371 7253.625 0.057
Police
 6 months 2130 460 1150 413
 12 months 2407 1249 1288 310
 Total (unadjusted) 4537 1332 2438 550
 Total (adjusted) 4499 1112 2476 912 2023.223 − 842.815 4889.261 0.165
Total CJS
 6 months 7434 906 5021 866
 12 months 8683 1709 5581 943
 Total (unadjusted) 16,146 2031 10,637 1305
 Total (adjusted) 16,057 1843 10,728 1540 5329.257 464.327 10,194.186 0.032
 Total inc. Engager (adjusted) 16,894 1941 10,701 1534 6192.966 1083.378 11,302.550 0.018
Accommodation
 6 months 3153 809 2943 917
 12 months 4735 1594 5899 1718
 Total (unadjusted) 7888 1869 8842 1971
 Total (adjusted) 7886 1916 8844 1921 − 958.558 − 6428.064 4510.947 0.726
Productivity
 6 months 3560 1013 3095 808
 12 months 3921 1133 4870 1454
 Total (unadjusted) 7481 1509 7965 1837
 Total (adjusted) 8282 1514 7157 1816 1124.992 − 3491.543 5741.527 0.628
Education
 Pre-release 544 129 485 123
 6 months 117 45 49 29
 12 months 190 71 28 9
 Total (unadjusted) 852 149 563 128
 Total (adjusted) 849 138 566 138 282.865 − 92.505 658.236 0.139
Other services
 Pre-release 56 12 41 9
 6 months 470 106 229 45
 12 months 400 196 433 134
 Total (unadjusted) 926 239 704 147
 Total (adjusted) 926 214 703 182 222.838 − 318.854 764.531 0.416
All costs minus productivity
 Pre-release 1006 148 882 147
 6 months 9452 1738 6663 1722
 12 months 14,067 2765 9387 2245
 Total (unadjusted) 24,525 3376 16,932 3090
 Total (adjusted) 23,327 3254 18,138 3109 5189.067 − 3726.096 14,104.231 0.250
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using MICE and adjusting for baseline and centre. The 
adjusted imputed difference in criminal justice costs includ-
ing the cost of the Engager intervention is £6193 (95% CI 
£1083–£11,303) per participant; for all costs minus produc-
tivity and including the costs of the intervention the imputed 
adjusted difference in costs is £6,035 (95% CI − £2,877 to 
£14,947) per participant.
QALYs and capability gains
Descriptive statistics for the imputed CORE-6D, EQ-5D-5L 
(cross-walk and TTO tariff) and ICECAP-A tariff are 
reported in Table 5. There was no significant difference in 
QALYs or YFC for any of the analyses. The complete case 
results are reported in Supplementary Material 3.
Table 4  (continued)
N = 140 N = 139 Adjusted  differencea 95% CI 95% CI p value
Mean SE Mean SE
 Total inc. Engager (adjusted) 24,177 3253 18,142 3108 6034.631 − 2878.161 14,947.420 0.182
SD standard deviation, SE standard error, CI confidence interval, CJS criminal justice system
a Adjusted difference: adjusted for baseline, with centre as a covariate
Table 5  Multiple imputation 
by chained equations utilities, 
capability and QALYs,
SE standard error, CI confidence interval, QALYs quality-adjusted life years, YFC years of full capability
a Adjusted difference: adjusted for baseline, with centre as a covariate
Engager Usual care Adjusted 
 differencea
95% CI 95% CI p value
N = 140 C
Mean SE Mean SE
CORE-6D
 1 month 0.743 0.022 0.761 0.024
 3 months 0.741 0.020 0.768 0.020
 6 months 0.753 0.019 0.780 0.019
 12 months 0.752 0.024 0.693 0.036
 QALYs (unadjusted) 0.749 0.013 0.751 0.015
 QALYs (adjusted) 0.743 0.012 0.757 0.014 − 0.014 − 0.052 0.023 0.455
EQ-5D-5L Crosswalk
 3 months 0.695 0.026 0.679 0.028
 6 months 0.695 0.022 0.707 0.026
 12 months 0.733 0.031 0.631 0.042
 QALYs (unadjusted) 0.703 0.017 0.675 0.019
 QALYs (adjusted) 0.698 0.015 0.680 0.016 0.019 − 0.023 0.039 0.379
EQ-5D-5L Tariff
 3 months 0.778 0.021 0.765 0.022
 6 months 0.768 0.021 0.785 0.021
 12 months 0.796 0.028 0.757 0.034
 QALYs (unadjusted) 0.777 0.016 0.769 0.017
 QALYs (adjusted) 0.774 0.013 0.772 0.014 0.002 − 0.036 0.027 0.919
ICECAP-A
 3 months 0.636 0.026 0.632 0.027
 6 months 0.651 0.022 0.694 0.024
 12 months 0.690 0.037 0.707 0.031
 YFC (unadjusted) 0.652 0.016 0.673 0.018
 YFC (adjusted) 0.652 0.015 0.673 0.015 − 0.021 − 0.064 0.022 0.335
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ICER, CEAC and CEP
For the primary economic evaluation, within-trial cost-effec-
tiveness analysis over 12 months, from a health and social 
care cost perspective with QALYs calculated using CORE-
6D, MICE used for missing cost and utility data and seem-
ingly unrelated regression to account for correlation between 
costs and outcomes, with adjustment for baseline and centre, 
there was a mean cost difference of £2738 (95% of iterations 
between £1030 and £4717) and a mean QALY difference 
of − 0.014 (95% of iterations between − 0.046 and 0.017): 
the Engager intervention is dominated by usual care. The 
CEP is reported in Fig. 2 and the CEAC in Supplementary 
Material 4. There is a 0% probability that the intervention 
is cost-effective for a £20,000 and £30,000 threshold for a 
QALY gained, if evaluated as a purely health care interven-
tion where decision to implement would be decided along 
the standard conventions for other new technologies in the 
English NHS. The CEP and CEAC for the secondary and 
sensitivity analyses are reported in Supplementary Material 
4. The conclusions remain consistent for all of the analyses 
conducted.
Cost‑consequences
Table 6 reports the results of the consequences component 
of the cost-consequences analysis. Paid employment and 
contact with service use are reported as odds; planned and 
unplanned service use were analysed using general linear 
models and either negative binomial or Poisson depending 
on the most appropriate model as indicated by the AIC [57].
The odds of being in contact with substance misuse ser-
vices were greater in the intervention group at 6 months 
after release (2.208 95% CI 1.197–3.633) and 12 months 
after release (2.244 95% CI 1.304–3.861). The results for 
unplanned service use are mixed, with more unplanned men-
tal health contacts at 12 months after release in participants 
randomised to Engager (1.326 95% CI 0.059–2.593), an 
increase in physical health unplanned contacts at 6 months 
after release (0.723 95% CI 0.089–1.358), but a decrease 
in unplanned physical health contacts at 12 months after 
release (− 0.701 95% CI − 1.381 to − 0.020). Unplanned 
contact with other services was also higher in the Engager 
group pre-release (0.379 95% CI 0.016–0.743). There was 
no significant impact on the odds of being in paid employ-
ment, accessing education, access to help with finances or 
accommodation.
Discussion
There was no evidence that the Engager intervention was 
cost-effective compared to usual care; this was the case 
across all secondary and sensitivity analyses. Overall, there 
was no significant difference in QALYs or YFC between 
Engager intervention arm participants and usual care partici-
pants. The intervention group cost significantly more from a 
health service cost perspective, with almost half of the esti-
mated incremental cost per person coming from the Engager 
intervention itself. It also cost significantly more from other 
public service perspectives such as criminal justice. On the 
other hand, there was evidence for a productivity gain in the 
Engager group in the complete case analysis, although this 
Fig. 2  Cost-effectiveness plane 
of Engager compared to usual 
care from a health and social 
care cost perspective over 
12 months with QALYs calcu-
lated using the CORE-6D
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difference was no longer significant in the imputed results 
and there was no evidence of increased employment in the 
analysis of consequences, suggesting this result may have 
been by chance.
Very few economic evaluations are carried out in crimi-
nal justice settings, with self-reported outcomes in this 
group being particularly hard to collect due to the transient 
nature of the population. This trial though presents a sig-
nificant contribution to the health economic evidence base 
for this population group. It also demonstrates the complex-
ity of economic evaluations in this area, with the results 
of the analysis having implications for a number of deci-
sion makers, including health care, criminal justice and 
local authorities. Costs and outcomes have been reported 
Table 6  Consequences of Engager intervention compared to usual care: odds ratios and general linear models
OR odds ratio adjusting for baseline and centre, AD adjusted difference, adjusting for baseline and centre, CI confidence interval
Engager Usual care OR 95% CI Lower 95% CI Upper p value
n %(n) n %(n)
Paid employment
 Pre-incarceration 140 25.71% (36) 140 39.29% (55)
 Release to 6 months 92 19.57% (18) 90 25.56% (23) 0.952 0.437 2.078 0.903
 Release to 12 months 92 25.00% (23) 90 27.78% (25) 1.28 0.591 2.753 0.535
Contact with substance services
 Pre-baseline 140 33.57% (47) 140 34.29% (48)
 Baseline to pre-release 128 29.69% (38) 129 22.48% (29) 1.565 0.856 2.859 0.146
 Baseline to 6 months post-release 136 44.12% (60) 135 31.11% (42) 2.085 1.197 3.633 0.010
 Baseline to 12 months 136 49.26% (67) 135 34.07% (46) 2.244 1.304 3.861 0.004
Education
 Pre-baseline 140 43.57% (61) 140 35.71% (50)
 Pre-release 128 26.56% (34) 129 24.81% (32) 1.065 0.606 1.871 0.828
 Baseline to 6 months 130 34.62% (45) 129 27.13% (35) 1.395 0.8188 2.376 0.221
 Baseline to 12 months 130 36.15% (47) 129 27.13% (35) 1.484 0.873 2.523 0.145
Help with finances
 Pre-baseline 140 15.71% (22) 140 18.57% (26)
 Pre-release 128 23.44% (30) 129 19.38% (25) 1.337 0.708 2.524 0.370
 Baseline to 6 months 136 43.38% (59) 135 40.00% (54) 1.143 0.704 1.855 0.589
 Baseline to 12 months 136 47.79% (65) 135 47.41% (64) 1.010 0.626 1.629 0.967
Help with accommodation
 Pre-baseline 140 49.29% (69) 140 50.00% (70)
 Pre-release 128 25.78% (33) 129 22.48% (29) 1.336 0.680 2.625 0.400
 Baseline to 6 months 136 46.32% (63) 135 42.22% (57) 1.223 0.729 2.053 0.445
 Baseline to 12 months 136 53.68% (73) 135 48.15% (65) 1.277 0.776 2.101 0.336
Unplanned attendances n Mean (SD) n Mean (SD) ADb 95% CI lower 95% CI upper p value
Mental health
 Baseline 140 0.200 (0.614) 140 0.093 (0.414)
 6 months 92 0.196 (0.579) 90 0.100 (0.337) 0.487 − 0.407 1.381 0.285
 12 months 66 0.182 (0.579) 58 0.0517 (0.223) 1.326 0.059 2.593 0.040
Physical health—unplanned
 Baseline 140 0.293 (0.594) 140 0.136 (0.344)
 6 months 92 0.446 (1.252) 90 0.211 (0.571) 0.723 0.089 1.358 0.025
 12 months 66 0.197 (0.401) 58 0.397 (0.793) − 0.701 − 1.381 − 0.020 0.043
Other services
 Baseline 140 1.814 (4.551) 140 2.179 (5.206)
 Pre-release 128 1.141 (3.578) 129 0.729 (1.291) 0.379 0.016 0.743 0.041
 6 months 92 2.348 (6.591) 90 1.856 (7.602) 0.039 − 0.377 0.455 0.854
 12 months 66 2.242 (12.449) 58 1.810 (4.847) 0.034 − 0.498 0.565 0.902
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in a disaggregated way to facilitate interpretation by each 
respective decision maker, although no one decision maker 
is likely to advocate for implementing Engager based on 
these results. The complexity of providing services to multi-
need clients across a number of public sector agencies is not 
new, with individuals with needs relating to mental health, 
physical health, housing, substance misuse, monetary and 
family relations being common in criminal justice, sub-
stance misuse and specialist mental health settings. Given 
that addressing one need, such as substance misuse, may 
have benefits that fall on other providers, such as criminal 
justice, initiatives such as pooled budgets across providers 
have been trialled to allow for the free flowing of money 
and outcomes across traditional barriers to facilitate joined 
up working [59]. Results from pilots of these interventions 
though have been equivocal in finding evidence for improved 
effectiveness or efficiency as a result of these initiatives [60, 
61].
Although there was no evidence for benefit or cost-
effectiveness for the Engager intervention, the cost-conse-
quences analysis showed some signals for potential benefit, 
although the results are mixed. The most evident benefit was 
an increased odds of accessing substance misuse services 
seen in the participants randomised to Engager. Long-term 
studies such as the National Treatment Outcomes Research 
Study (NTORS) have shown the benefit of being in contact 
with substance misuse services in terms of reduced crimi-
nal activity and increased stable accommodation [58]. In 
NTORS, the evidence was that benefits accrued year on year 
over 5 years, hence the follow-up time of 12 months post-
release in Engager may not have been sufficient to identify 
the benefits to participants. The loss to follow-up may have 
also failed to capture some benefits. In NTORS, routine data 
were used to capture criminal convictions. This was explored 
as part of Engager, but barriers to accessing data and time 
constraints in regards to the programme ending meant that 
this was not feasible. Ideally, routine data should be obtained 
for participants in the trial at a later time point to observe if 
there are any long-term benefits of the intervention.
As part of the HEAP, we made a predetermined choice for 
the primary CUA to calculate QALYs using the CORE-6D 
as opposed to using the NICE ‘reference case’ EQ-5D [9]. 
This was based on analyses undertaken during the feasibility 
trial that the CORE-OM and associated CORE-6D tariff are 
more sensitive to changes in the clinical measure of depres-
sion, the PHQ-9, in men in prison. Previous studies have 
found that the EQ-5D is acceptable for use in common men-
tal health problems [62] and as the NICE ‘reference case’, it 
also allows for comparison of the results of economic evalu-
ations across disease areas. There is an issue though when 
the EQ-5D is not sensitive to changes in a specific clinical 
condition and/or patient group that this may result in less 
favourable resource allocation decisions for those areas. 
There is some evidence that the EQ-5D may not be suitable 
in prison populations, but additional research is required to 
explore this further. The ICECAP-A, designed to measure 
wider considerations than health-related quality of life, also 
did not appear to capture anything additional in this popula-
tion group. The results remain the same regardless though 
of the specific outcome measure used.
Overall, there is a challenge when evaluating interven-
tions such as Engager which are designed to improve access 
to health and social care services for hard to reach groups. 
There is strong evidence that people who have spent time 
in prison are less likely to access health care services than 
their peers in the general population [6]. This group also 
strongly overlap with homeless and substance misuse popu-
lations who also show less health care service use relative 
to need than the wider population [63]. The consequences 
component of the cost-consequences analysis provided some 
evidence for increased access to services such as substance 
misuse services, but it also showed an increase in unplanned 
service use, particularly for specialist mental health services 
(noting that only one mental health service use was iden-
tified as planned). What is difficult to evaluate from this 
result is if this is a sign of improved access to mental health 
services as a result of the Engager intervention, or if the 
Engager intervention was linked to worsening mental health. 
In addition, to note that this is complicated by people in the 
Engager intervention group being a more severe group at 
baseline by chance, and although we adjusted for baseline 
mental health contacts this may have continued to skew the 
results.
In CUA, the aim is that additional costs arising from 
increased service use to meet identified needs is usually 
balanced out by additional gains in health-related quality of 
life, such that for new treatments NICE has a threshold of 
paying £30,000 per additional QALY gained [9]. There was 
no evidence though for improved QALYs or YFC as a result 
of the intervention. This may be due to the intervention not 
being effective in these areas, but it may also be due to these 
measures not being suitable in this population group, bias 
as a result of loss to follow-up or the time-horizon of the 
analysis being too short, particularly if in the short term the 
intervention required people to work through painful mental 
health or substance misuse problems.
One of the challenges associated with conducting 
research in prisons is loss to follow-up for patient-completed 
measures: this may explain why other trials in prisons have 
not included a preference-based outcome as part of their 
economic evaluation. The follow-up up rate of 66% for the 
primary clinical outcome at 6 months is high compared to 
most studies in prisons [17]. Contacting people following 
prison contains a range of issues including temporary hous-
ing, changing contact details as well as increased mental 
and physical problems that can make people difficult to 
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contact. Unfortunately, there is also a nefarious aspect to 
this: those who may have returned to substance misuse and 
the criminal activities to support it may be more difficult to 
contact and actively want to avoid being contacted (although 
noting self-reported substance misuse problems at baseline 
were not a predictor of missing data at follow-up). Related 
to this, one of the more unexpected findings of the trial is 
that the Engager intervention group had significantly higher 
criminal justice costs. Measuring criminal activity is noto-
riously difficult; self-report measures of crime, in addition 
to being unreliable, may also have a negative impact on the 
relationship between the researcher and the trial participant, 
regardless of what reassurances of anonymity are provided 
[64]. Engager included no self-report measure of crime for 
this reason. The intention had been to obtain Police National 
Computer (PNC) data for the whole sample but this was 
in the end not possible. We could, therefore, only include 
the proxy measure of reported contact with police or being 
in custody. Although arguably more objective than self-
report involvement in crime, this only measures if people 
are caught being involved in criminal activity, not the fre-
quency with which the criminal activity occurs. One of the 
potential benefits of the Engager intervention is improved 
contacts with services; the implications of this may have 
been that this made people more visible to criminal justice 
agencies and hence more likely to be picked up for crimes. 
We were also unable to include implications of the wider 
costs, particularly to victims, of criminal activity.
Finally, there were some challenges in the delivery of 
the Engager intervention, with not all participants engaging 
with the intervention, and some discontinuity in the practi-
tioners delivering the intervention due to staff turn-over and 
illness [16]. It is possible that embedding the training and 
delivery of Engager in already existing teams and making 
it part of normal delivery may reduce the cost of delivering 
the intervention and improve engagement. Further work is 
required to evaluate the implications for the cost and clinical 
effectiveness of these changes.
Conclusion
The above economic evaluation is one of the few CUA con-
ducted for a prison-based intervention. Although there was 
no evidence that the Engager intervention was cost-effective, 
it provides evidence for the feasibility of conducting CUA 
in this population. Future research though should consider 
supplementing the analysis with routine data and increas-
ing the follow-up duration. It demonstrates the importance 
of including resource use and cost information to cover a 
wide array of decision makers as health interventions for 
prison have implications beyond health care, and reporting 
the results in a disaggregated way.
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